Bristlecone Advisors’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $4.71M | Sell |
16,673
-421
| -2% | -$122K | 0.39% | 50 |
|
|
2025
Q2 | $4.77M | Sell |
17,094
-664
| -4% | -$188K | 0.4% | 49 |
|
|
2025
Q1 | $5.53M | Buy |
17,758
+149
| +0.8% | +$44K | 0.45% | 50 |
|
|
2024
Q4 | $4.59M | Sell |
17,609
-88
| -0.5% | -$26.1K | 0.36% | 55 |
|
|
2024
Q3 | $5.7M | Sell |
17,697
-154
| -0.9% | -$50.4K | 0.46% | 49 |
|
|
2024
Q2 | $5.58M | Sell |
17,851
-99
| -0.6% | -$29.1K | 0.48% | 47 |
|
|
2024
Q1 | $5.1M | Buy |
17,950
+457
| +3% | +$134K | 0.45% | 49 |
|
|
2023
Q4 | $5.04M | Sell |
17,493
-372
| -2% | -$101K | 0.51% | 44 |
|
|
2023
Q3 | $4.8M | Buy |
17,865
+532
| +3% | +$133K | 0.54% | 43 |
|
|
2023
Q2 | $3.85M | Sell |
17,333
-882
| -5% | -$205K | 0.39% | 48 |
|
|
2023
Q1 | $4.4M | Buy |
18,215
+1,014
| +6% | +$249K | 0.48% | 43 |
|
|
2022
Q4 | $4.52M | Sell |
17,201
-365
| -2% | -$97.8K | 0.55% | 39 |
|
|
2022
Q3 | $3.96M | Buy |
17,566
+85
| +0.5% | +$20.6K | 0.52% | 43 |
|
|
2022
Q2 | $4.25M | Buy |
17,481
+2,414
| +16% | +$592K | 0.53% | 41 |
|
|
2022
Q1 | $3.64M | Buy |
15,067
+16
| +0.1% | +$3.68K | 0.45% | 47 |
|
|
2021
Q4 | $3.39M | Sell |
15,051
-3,404
| -18% | -$718K | 0.41% | 57 |
|
|
2021
Q3 | $3.92M | Buy |
18,455
+80
| +0.4% | +$18.4K | 0.51% | 45 |
|
|
2021
Q2 | $4.48M | Sell |
18,375
-506
| -3% | -$124K | 0.61% | 41 |
|
|
2021
Q1 | $4.7M | Sell |
18,881
-20
| -0.1% | -$4.77K | 0.71% | 31 |
|
|
2020
Q4 | $4.35M | Buy |
18,901
+149
| +0.8% | +$34.4K | 0.69% | 33 |
|
|
2020
Q3 | $4.77M | Sell |
18,752
-496
| -3% | -$123K | 0.87% | 28 |
|
|
2020
Q2 | $4.54M | Sell |
19,248
-118
| -0.6% | -$26.9K | 0.92% | 26 |
|
|
2020
Q1 | $3.93M | Sell |
19,366
-1,668
| -8% | -$364K | 0.94% | 24 |
|
|
2019
Q4 | $5.07M | Buy |
21,034
+1,413
| +7% | +$311K | 1.02% | 23 |
|
|
2019
Q3 | $3.8M | Sell |
19,621
-1,563
| -7% | -$300K | 0.92% | 26 |
|
|
2019
Q2 | $3.9M | Buy |
21,184
+1,583
| +8% | +$283K | 0.93% | 25 |
|
|
2019
Q1 | $3.72M | Buy |
19,601
+135
| +0.7% | +$25.8K | 1.04% | 25 |
|
|
2018
Q4 | $3.79M | Sell |
19,466
-215
| -1% | -$41.9K | 1.14% | 21 |
|
|
2018
Q3 | $4.08M | Buy |
19,681
+7,250
| +58% | +$1.43M | 1.03% | 25 |
|
|
2018
Q2 | $2.29M | Sell |
12,431
-1,316
| -10% | -$233K | 0.76% | 28 |
|
|
2018
Q1 | $2.34M | Sell |
13,747
-3,400
| -20% | -$624K | 0.79% | 31 |
|
|
2017
Q4 | $2.98M | Buy |
17,147
+310
| +2% | +$54.9K | 0.95% | 30 |
|
|
2017
Q3 | $3.14M | Buy |
16,837
+30
| +0.2% | +$5.32K | 1.02% | 22 |
|
|
2017
Q2 | $2.9M | Buy |
16,807
+524
| +3% | +$85.2K | 0.98% | 23 |
|
|
2017
Q1 | $2.67M | Buy |
16,283
+186
| +1% | +$30.9K | 0.93% | 27 |
|
|
2016
Q4 | $2.35M | Sell |
16,097
-530
| -3% | -$79.8K | 0.84% | 34 |
|
|
2016
Q3 | $2.77M | Sell |
16,627
-935
| -5% | -$158K | 1% | 23 |
|
|
2016
Q2 | $2.67M | Buy |
17,562
+2,948
| +20% | +$458K | 0.99% | 27 |
|
|
2016
Q1 | $2.19M | Buy |
14,614
+3,845
| +36% | +$571K | 0.87% | 35 |
|
|
2015
Q4 | $1.75M | Buy |
+10,769
| New | +$1.69M | 0.74% | 42 |
|
Other funds holding AMGN
Bristlecone Advisors's AMGN Position: Q3 2025 in Review
Bristlecone Advisors reduced its Amgen (AMGN) stake by 2.5% in Q3 2025, selling an estimated $122K and leaving 16,673 shares worth $4.71M. The position accounts for 0.39% of the portfolio, ranked #50.
Bristlecone Advisors first reported a position in AMGN in Q4 2015 and has held it in 40 quarters since. The position peaked at $5.7M in Q3 2024. 2,819 funds tracked by Wall St. Rank hold AMGN as of Q3 2025.
- Bristlecone Advisors held 16,673 shares of Amgen worth $4.71M as of Q3 2025.
- Bristlecone Advisors sold 421 Amgen shares in Q3 2025, an estimated $122K.
- Amgen made up 0.39% of Bristlecone Advisors's portfolio in Q3 2025, its #50 holding.
- Bristlecone Advisors first reported a position in Amgen in Q4 2015 and has held it in 40 quarters since.
- Bristlecone Advisors's Amgen position peaked at $5.7M in Q3 2024.
- 2,819 funds tracked by Wall St. Rank held Amgen as of Q3 2025.
Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.